Aethlon Medical Stock Price, News & Analysis

Aethlon Medical (Nasdaq: AEMD) announced positive safety review results from the independent Data Safety Monitoring Board (DSMB) for its ongoing clinical trial AEMD-2022-06 of the Aethlon Hemopurifier®. The trial is evaluating the device's safety and optimal dosing in cancer patients with stable or progressive disease while on Pembrolizumab or Nivolumab treatment.

The DSMB reviewed data from the initial three-patient cohort, who each received a single 4-hour Hemopurifier treatment, finding no safety concerns or serious adverse events. The board recommended advancing to Cohort 2, where participants will receive two Hemopurifier treatments over one week. The trial aims to enroll 9-18 patients across three Australian clinical sites.

The study targets patients among the 60-70% who don't respond well to anti-PD-1 immunotherapy, with findings intended to inform future Premarket Approval studies.

Aethlon Medical (Nasdaq: AEMD) reported financial results for Q4 FY2025 and provided corporate updates. Key highlights include treatment of three patients in the Hemopurifier® cancer trial in Australia, regulatory approval in India, and significant operational cost reductions. The company's cash balance stood at $5.5 million as of March 31, 2025.

Operating expenses decreased by 26% to $9.3 million from $12.6 million year-over-year. Preclinical data showed 98.5% removal of platelet-derived EVs in simulated Hemopurifier® treatment. The company is expanding research into Long COVID applications through collaboration with UCSF, addressing a market affecting 44-48 million people in the US.

Aethlon Medical (NASDAQ: AEMD), a medical therapeutic company specializing in cancer and infectious disease treatments, has scheduled its fiscal fourth quarter 2025 financial results release for June 26, 2025, at 4:15 p.m. ET. The company will host a conference call at 4:30 p.m. ET the same day, featuring management presentations and a Q&A session. Participants can pre-register online or dial in directly, with both domestic and international lines available. A replay of the call will be accessible until July 26, 2025, through multiple channels including the company's website and various replay numbers.

Aethlon Medical (AEMD) has announced the successful treatment of a second patient with its Hemopurifier device in an Australian clinical trial. The trial focuses on patients with solid tumors who haven't responded to anti-PD-1 therapies like Keytruda or Opdivo. Both treated patients completed 4-hour Hemopurifier sessions without complications and finished the 7-day safety follow-up period. The trial will include approximately 18 patients, with the first cohort requiring three patients before a Data Safety Monitoring Board review. The Hemopurifier is designed to remove tumor-produced EVs from bloodstream, potentially improving response rates to anti-PD-1 antibodies. The study aims to determine optimal treatment frequency and examine if reducing EV concentrations enhances the body's natural tumor-fighting ability.

Aethlon Medical (NASDAQ: AEMD) announced its upcoming presentation of new pre-clinical data at the Keystone Symposium on Long COVID in August 2025. The presentation will focus on their Hemopurifier® device's ability to bind extracellular vesicles (EVs) in Long COVID samples. The study, conducted in collaboration with UC San Francisco Medical Center, examines how EVs from Long COVID patients bind to the device's proprietary affinity resin containing Galanthus nivalis agglutinin. Long COVID affects 44-48 million Americans with a $2 billion economic burden for year-long cases. The Hemopurifier® is designed to remove harmful EVs from blood and has previously shown success in treating severe acute COVID-19. The poster presentation (Number 2001) will be delivered by CMO Steven P. LaRosa on August 12, 2025.

Aethlon Medical (NASDAQ: AEMD) has published preclinical data demonstrating its Hemopurifier® device achieved 98.5% removal of platelet-derived extracellular vesicles (PD-EVs) from plasma in a simulated 4-hour treatment. The study, published in bioRxiv, validates the device's potential in treating multiple diseases. The Hemopurifier® uses a proprietary Galanthus nivalis agglutinin (GNA) affinity resin to filter harmful EVs and viruses from blood. PD-EVs, the most numerous EV population in the body, are implicated in various conditions including cancer, lupus, systemic sclerosis, multiple sclerosis, Alzheimer's disease, sepsis, and Long COVID. The results support Aethlon's ongoing oncology clinical trial in Australia and suggest potential applications across multiple therapeutic areas.

Aethlon Medical (NASDAQ: AEMD) has published preclinical study results in Transplant Immunology demonstrating new potential applications for its Hemopurifier® blood filtration system in organ transplantation. The study, published February 28, 2025, shows the device's effectiveness in removing harmful extracellular vesicles (EVs) and microRNAs from renal perfusates of discarded donor kidneys.

The research indicates significant reductions in EVs and microRNAs linked to renal dysfunction, suggesting potential benefits for kidney transplant outcomes. This expands the Hemopurifier's therapeutic potential beyond its current applications in virology and oncology, presenting what the company calls a "pipeline within a device."

While the company's primary focus remains on Australian and India Oncology trials, these findings suggest the technology could potentially be integrated with existing organ preservation systems, though further evaluation and clinical trials would be necessary.

Aethlon Medical (NASDAQ: AEMD), a medical therapeutic company developing products for cancer and life-threatening infectious diseases, will present at the Emerging Growth Conference on February 19, 2025. The company's CEO, James Frakes, will deliver a 30-minute presentation starting at 11:25 AM Eastern time.

This interactive online event offers shareholders and the investment community the opportunity to engage directly with Mr. Frakes in real-time. Participants can submit questions in advance to Questions@EmergingGrowth.com or during the live session.

For those unable to attend live, an archived webcast will be available on EmergingGrowth.com and the Emerging Growth YouTube Channel. Registration is required through the provided webcast link to attend and receive updates.

Aethlon Medical (NASDAQ: AEMD) reported its fiscal Q3 2024 results and key developments. The company achieved a significant milestone with the first patient treated in their Hemopurifier® cancer trial in Australia on January 29, 2025. The treatment was completed successfully with no device-related complications.

The company implemented protocol modifications to improve trial efficiency, including changes to patient enrollment criteria and broadening eligibility requirements. Two clinical sites are currently active in Australia, with a third site expected to activate in February 2025.

Financial highlights include a cash balance of $4.8 million as of December 31, 2024. Operating expenses decreased by 50% to $1.8 million compared to $3.6 million in the same quarter last year, primarily due to reduced payroll expenses, professional fees, and general administrative costs. Net loss decreased to $1.8 million from $3.5 million in the prior year period.